Select Clinical Trial
Gastroesophageal Junction Cancer
GS-US-296-1080: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Men and women, ages 18 and older, diagnosed with cancer of the stomach or gastroesophageal junction. For more information, please contact the study coordinator at 910-715-2200.